OGC
GILD icon

Oak Grove Capital’s Gilead Sciences GILD Stock Holding History

Oak Grove Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-400
Closed -$25K – 91
2021
Q4 		$25K Hold
400
– – ﹤0.01% 104
2021
Q3 		$1K Hold
400
– – ﹤0.01% 108
2021
Q2 		$1K Hold
400
– – ﹤0.01% 110
2021
Q1 		$1K Hold
400
– – ﹤0.01% 102
2020
Q4 		$1K Buy
+400
New +$24.1K ﹤0.01% 84

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Oak Grove Capital's GILD Position: Q1 2026 in Review

Oak Grove Capital held its Gilead Sciences (GILD) position steady in Q1 2026 at 2,800 shares worth $390K. The position accounts for 0.03% of the portfolio, ranked #78.

Oak Grove Capital first reported a position in GILD in Q4 2017 and has held it in 26 quarters since. The position peaked at $12.9M in Q4 2019. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Oak Grove Capital held 2,800 shares of Gilead Sciences worth $390K as of Q1 2026.
  • Oak Grove Capital left its Gilead Sciences share count unchanged in Q1 2026.
  • Gilead Sciences made up 0.03% of Oak Grove Capital's portfolio in Q1 2026, its #78 holding.
  • Oak Grove Capital first reported a position in Gilead Sciences in Q4 2017 and has held it in 26 quarters since.
  • Oak Grove Capital's Gilead Sciences position peaked at $12.9M in Q4 2019.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Oak Grove Capital's 13F filing for Q1 2026, filed 13 May 2026.